HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 279, Issue 38, 39915-39924, September 17, 2004

This Article Full Text Full Text (PDF) All Versions of this Article: 279/38/39915    most recent M404795200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kirchhofer, D. Articles by Lazarus, R. A. Search for Related Content PubMed PubMed Citation Articles by Kirchhofer, D. Articles by Lazarus, R. A. Social Bookmarking                      What's this?

Structural and Functional Basis of the Serine Protease-like Hepatocyte Growth Factor -Chain in Met Binding and Signaling^*

Daniel Kirchhofer, Xiaoyi Yao¶||, Mark Peek, Charles Eigenbrot¶, Michael T. Lipari, Karen L. Billeci**, Henry R. Maun¶, Paul Moran, Lydia Santell¶, Christian Wiesmann¶, and Robert A. Lazarus¶

From the Departments of Physiology, ^¶Protein Engineering, and ^**Assay and Automation Technology, Genentech, Inc., South San Francisco, California 94080 and Institute for Biology III, University of Freiburg, Schaenzlestrasse 1, D-79104 Freiburg, Germany

Hepatocyte growth factor (HGF), a plasminogen-related growth factor, is the ligand for Met, a receptor tyrosine kinase implicated in development, tissue regeneration, and invasive tumor growth. HGF acquires signaling activity only upon proteolytic cleavage of single-chain HGF into its / heterodimer, similar to zymogen activation of structurally related serine proteases. Although both chains are required for activation, only the -chain binds Met with high affinity. Recently, we reported that the protease-like HGF -chain binds to Met with low affinity (Stamos, J., Lazarus, R. A., Yao, X., Kirchhofer, D., and Wiesmann, C. (2004) EMBO J. 23, 2325-2335). Here we demonstrate that the zymogen-like form of HGF also binds Met, albeit with 14-fold lower affinity than the protease-like form, suggesting optimal interactions result from conformational changes upon cleavage of the single-chain form. Extensive mutagenesis of the HGF region corresponding to the active site and activation domain of serine proteases showed that 17 of the 38 purified two-chain HGF mutants resulted in impaired cell migration or Met phosphorylation but no loss in Met binding. However, reduced biological activities were well correlated with reduced Met binding of corresponding mutants of HGF itself in assays eliminating dominant -chain binding contributions. Moreover, the crystal structure of HGF determined at 2.53 Å resolution provides a structural context for the mutagenesis data. The functional Met binding site is centered on the "active site region" including "triad" residues Gln⁵³⁴ [c57], Asp⁵⁷⁸ [c102], and Tyr⁶⁷³ [c195] and neighboring "activation domain" residues Val⁶⁹², Pro⁶⁹³, Gly⁶⁹⁴, Arg⁶⁹⁵, and Gly⁶⁹⁶ [c214-c219]. Together they define a region that bears remarkable resemblance to substrate processing regions of serine proteases. Models of HGF-dependent Met receptor activation are discussed.

Received for publication, April 29, 2004 , and in revised form, June 22, 2004.

The atomic coordinates and structure factors (code 1SI5) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

^* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^|| Present address: Dept. of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409.

To whom correspondence may be addressed: Dept. of Physiology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. Tel.: 650-225-2134; Fax: 650-225-6327; E-mail: dak{at}gene.com.

To whom correspondence may be addressed: Dept. of Protein Engineering, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. Tel.: 650-225-1166; Fax: 650-225-3734; E-mail: laz{at}gene.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Basilico, A. Arnesano, M. Galluzzo, P. M. Comoglio, and P. Michieli A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met J. Biol. Chem., July 25, 2008; 283(30): 21267 - 21277. [Abstract] [Full Text] [PDF]

				D. Kirchhofer, M. T. Lipari, L. Santell, K. L. Billeci, H. R. Maun, W. N. Sandoval, P. Moran, J. Ridgway, C. Eigenbrot, and R. A. Lazarus Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist PNAS, March 27, 2007; 104(13): 5306 - 5311. [Abstract] [Full Text] [PDF]

				E. Gherardi, S. Sandin, M. V. Petoukhov, J. Finch, M. E. Youles, L.-G. Ofverstedt, R. N. Miguel, T. L. Blundell, G. F. Vande Woude, U. Skoglund, et al. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. PNAS, March 14, 2006; 103(11): 4046 - 4051. [Abstract] [Full Text] [PDF]

				T. Burgess, A. Coxon, S. Meyer, J. Sun, K. Rex, T. Tsuruda, Q. Chen, S.-Y. Ho, L. Li, S. Kaufman, et al. Fully Human Monoclonal Antibodies to Hepatocyte Growth Factor with Therapeutic Potential against Hepatocyte Growth Factor/c-Met-Dependent Human Tumors Cancer Res., February 1, 2006; 66(3): 1721 - 1729. [Abstract] [Full Text] [PDF]